{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:28:54Z","timestamp":1775197734259,"version":"3.50.1"},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14764","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:41:15Z","timestamp":1729514475000},"source":"Crossref","is-referenced-by-count":2,"title":["Impact of bortezomib on 1q21+ in multiple myeloma: A meta-analysis of treatment outcomes and prognostic implications"],"prefix":"10.3892","volume":"29","author":[{"given":"Xiaona","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejie","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 610041 P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"key20241202101824_b1-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20241202101824_b2-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.13537","article-title":"Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century","volume":"171","author":"Pulte","year":"2015","journal-title":"Br J Haematol"},{"key":"key20241202101824_b3-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"188","DOI":"10.7861\/clinmedicine.19-2-188a","article-title":"Haematology: Multiple myeloma","volume":"19","author":"Cullis","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"key20241202101824_b4-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"key20241202101824_b5-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"key":"key20241202101824_b6-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/cells10061360","article-title":"Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets","volume":"10","author":"Burroughs Garc\u00eca","year":"2021","journal-title":"Cells"},{"key":"key20241202101824_b7-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with High-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"key":"key20241202101824_b8-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A european myeloma network (EMN) report within the HARMONY project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20241202101824_b9-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2147\/TACG.S262866","article-title":"Genetic predictors of mortality in patients with multiple myeloma","volume":"14","author":"Hassan","year":"2021","journal-title":"Appl Clin Genet"},{"key":"key20241202101824_b10-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/era.13.9","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"13","author":"McBride","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20241202101824_b11-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clml.2012.11.012","article-title":"Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib","volume":"13","author":"Smetana","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20241202101824_b12-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20241202101824_b13-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2013.088211","article-title":"Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value","volume":"99","author":"An","year":"2014","journal-title":"Haematologica"},{"key":"key20241202101824_b14-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2010.05.002","article-title":"Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains","volume":"35","author":"Chang","year":"2011","journal-title":"Leuk Res"},{"key":"key20241202101824_b15-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"key20241202101824_b16-ol-29-1-14764","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis","author":"Wells","year":"2000"},{"key":"key20241202101824_b17-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3904\/kjim.2016.195","article-title":"An overview of meta-analysis for clinicians","volume":"33","author":"Lee","year":"2018","journal-title":"Korean J Intern Med"},{"key":"key20241202101824_b18-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1634\/theoncologist.2019-0132","article-title":"1q21 Gain Combined with High-risk factors is a heterogeneous prognostic factor in newly diagnosed multiple myeloma: A multicenter study in China","volume":"24","author":"Li","year":"2019","journal-title":"Oncologist"},{"key":"key20241202101824_b19-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20241202101824_b20-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/10428194.2019.1700503","article-title":"1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib","volume":"61","author":"Du","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"key20241202101824_b21-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1084683","DOI":"10.3389\/fonc.2022.1084683","article-title":"The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"key20241202101824_b22-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"20406207221082043","DOI":"10.1177\/20406207221082043","article-title":"The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain","volume":"13","author":"Tang","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"key20241202101824_b23-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/17474086.2021.1983427","article-title":"Chromosomal 1q21 abnormalities in multiple myeloma: A review of translational, clinical research, and therapeutic strategies","volume":"14","author":"Bisht","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"key20241202101824_b24-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"key20241202101824_b25-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20241202101824_b26-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"key20241202101824_b27-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"key":"key20241202101824_b28-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"4705654","DOI":"10.1155\/2022\/4705654","article-title":"MSC Senescence-related genes are associated with myeloma prognosis and lipid metabolism-mediated resistance to proteasome inhibitors","volume":"2022","author":"Cao","year":"2022","journal-title":"J Oncol"},{"key":"key20241202101824_b29-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"key20241202101824_b30-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"key":"key20241202101824_b31-ol-29-1-14764","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","article-title":"The Importance of FISH Signal Cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: Is it underestimated?","volume":"22","author":"Gao","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T08:18:28Z","timestamp":1733127508000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14764","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"article-number":"18"}}